The
global Injection Pens/Injectable
Pens/Pen Injectors Market is expected to reach USD 67.9 billion by 2025, according to a new report by
Grand View Research, Inc., registering a 9.4%
CAGR during the forecast period. High demand for these devices for
management of various chronic as well as acute diseases and increasing
awareness in developing regions are key factors expected to drive the market.
Injectable
pens have witnessed significant success in improving patient convenience during
management of chronic disease, a process that might include administering
intermittent injections. These devices are more convenient and affordable than
other delivery systems. Ongoing studies on the same to assess their
applications in management of other diseases, including but not limited to
Hepatitis C and cancer, is expected to ensure swift market growth through 2025.
Browse
Details of Report @
https://www.grandviewresearch.com/industry-analysis/injection-pens-market
https://www.grandviewresearch.com/industry-analysis/injection-pens-market
Further key findings from the study suggest:
- Rising
incidence of diseases such as diabetes and arthritis is primarily boosting
market growth
- Increase in
government healthcare expenditure and availability of favorable healthcare
insurance policies in developed as well as developing countries is driving
the market
- By product,
reusable injectable pens are the largest and fastest growing segment owing
to the advantages associated with them such as cost effectiveness and
patient convenience. Commercially available reusable injectable pens
mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar,
Bydureon, Epipen and Genotropin
- By dosage,
variable dosage is the fastest growing segment. Some of the customizable
variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL
Group, and Evo pen by Copernicus
- North
America dominates the market, followed by Europe. Technological
advancements and increase in incidence of osteoporosis, arthritis, and
anaphylaxis are factors that can be attributable to its largest market
share
- Asia Pacific
is expected to be the fastest growing region over the forecast period.
Better accessibility to healthcare, coupled with constantly increasing
healthcare expenditure in the region, is fueling market growth
- China is one
of the most lucrative markets with tremendous growth opportunities for
global as well as local players. This is owing to favorable factors such
as availability of labor and raw materials at significantly lower prices
as compared to other regions
- Key players
in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly
and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz
Inc.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment